APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Receptor Type 2

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Somatostatin Receptor Type 2 Market Outlook and Growth Opportunities 2026

Report ID 174036950419 December 2025199 pages

Choose your research edition.

Industry ResearchSomatostatin Receptor Type 2 Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Receptor Type 2 Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Somatostatin Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Receptor Type 2 Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Receptor Type 2 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Somatostatin Receptor Type 2 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Somatostatin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Somatostatin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Somatostatin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Somatostatin Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Somatostatin Receptor Type 2 market include Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc and Zucara Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Somatostatin Receptor Type 2 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Somatostatin Receptor Type 2 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Somatostatin Receptor Type 2 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Somatostatin Receptor Type 2 market.

Somatostatin Receptor Type 2 Segment by Company

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Zucara Therapeutics Inc

Somatostatin Receptor Type 2 Segment by Type

CRN-00808

PRL-2903

Lanreotide Acetate

Others

Somatostatin Receptor Type 2 Segment by Application

Oncology

Hormonal Disorder

Metabolic Disorder

Others

Somatostatin Receptor Type 2 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Somatostatin Receptor Type 2 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Somatostatin Receptor Type 2 key companies, revenue, market share, and recent developments.

3. To split the Somatostatin Receptor Type 2 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Somatostatin Receptor Type 2 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Somatostatin Receptor Type 2 significant trends, drivers, influence factors in global and regions.

6. To analyze Somatostatin Receptor Type 2 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Receptor Type 2.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Somatostatin Receptor Type 2 industry.

Chapter 3: Detailed analysis of Somatostatin Receptor Type 2 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Somatostatin Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Somatostatin Receptor Type 2 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Somatostatin Receptor Type 2 Industry Trends Table 2. Somatostatin Receptor Type 2 Industry Drivers Table 3. Somatostatin Receptor Type 2 Industry Opportunities and Challenges Table 4. Somatostatin Receptor Type 2 Industry Restraints Table 5. Global Somatostatin Receptor Type 2 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Somatostatin Receptor Type 2 Revenue Share by Company (2021-2026) Table 7. Global Somatostatin Receptor Type 2 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Somatostatin Receptor Type 2 Key Company Manufacturing Base & Headquarters Table 9. Global Somatostatin Receptor Type 2 Company, Product Type & Application Table 10. Global Somatostatin Receptor Type 2 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Somatostatin Receptor Type 2 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CRN-00808 Table 15. Significant Companies of PRL-2903 Table 16. Significant Companies of Lanreotide Acetate Table 17. Significant Companies of Others Table 18. Global Somatostatin Receptor Type 2 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Somatostatin Receptor Type 2 Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Somatostatin Receptor Type 2 Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Somatostatin Receptor Type 2 Sales Value Share by Type (2021-2026) Table 22. Global Somatostatin Receptor Type 2 Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Oncology Table 24. Significant Companies of Hormonal Disorder Table 25. Significant Companies of Metabolic Disorder Table 26. Significant Companies of Others Table 27. Global Somatostatin Receptor Type 2 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Somatostatin Receptor Type 2 Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Somatostatin Receptor Type 2 Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Somatostatin Receptor Type 2 Sales Value Share by Application (2021-2026) Table 31. Global Somatostatin Receptor Type 2 Sales Value Share by Application (2027-2032) Table 32. Global Somatostatin Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Somatostatin Receptor Type 2 Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Somatostatin Receptor Type 2 Sales Value Share by Region (2021-2026) Table 35. Global Somatostatin Receptor Type 2 Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Somatostatin Receptor Type 2 Sales Value Share by Region (2027-2032) Table 37. Global Somatostatin Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Somatostatin Receptor Type 2 Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Somatostatin Receptor Type 2 Sales Value Market Share by Country (2021-2026) Table 40. Global Somatostatin Receptor Type 2 Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Somatostatin Receptor Type 2 Sales Value Market Share by Country (2027-2032) Table 42. Amryt Pharma plc Company Information Table 43. Amryt Pharma plc Business Overview Table 44. Amryt Pharma plc Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Amryt Pharma plc Somatostatin Receptor Type 2 Product Portfolio Table 46. Amryt Pharma plc Recent Development Table 47. Crinetics Pharmaceuticals Inc Company Information Table 48. Crinetics Pharmaceuticals Inc Business Overview Table 49. Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio Table 51. Crinetics Pharmaceuticals Inc Recent Development Table 52. Daewoong Pharmaceutical Co Ltd Company Information Table 53. Daewoong Pharmaceutical Co Ltd Business Overview Table 54. Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Product Portfolio Table 56. Daewoong Pharmaceutical Co Ltd Recent Development Table 57. Ipsen SA Company Information Table 58. Ipsen SA Business Overview Table 59. Ipsen SA Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Ipsen SA Somatostatin Receptor Type 2 Product Portfolio Table 61. Ipsen SA Recent Development Table 62. Progenics Pharmaceuticals Inc Company Information Table 63. Progenics Pharmaceuticals Inc Business Overview Table 64. Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio Table 66. Progenics Pharmaceuticals Inc Recent Development Table 67. Strongbridge Biopharma plc Company Information Table 68. Strongbridge Biopharma plc Business Overview Table 69. Strongbridge Biopharma plc Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Strongbridge Biopharma plc Somatostatin Receptor Type 2 Product Portfolio Table 71. Strongbridge Biopharma plc Recent Development Table 72. Zucara Therapeutics Inc Company Information Table 73. Zucara Therapeutics Inc Business Overview Table 74. Zucara Therapeutics Inc Somatostatin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Zucara Therapeutics Inc Somatostatin Receptor Type 2 Product Portfolio Table 76. Zucara Therapeutics Inc Recent Development Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Somatostatin Receptor Type 2 Product Image Figure 2. Global Somatostatin Receptor Type 2 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Receptor Type 2 Market Size (2021-2032) & (US$ Million) Figure 4. Global Somatostatin Receptor Type 2 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CRN-00808 Image Figure 8. PRL-2903 Image Figure 9. Lanreotide Acetate Image Figure 10. Others Image Figure 11. Global Somatostatin Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Somatostatin Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Somatostatin Receptor Type 2 Sales Value Share by Type (2021-2032) Figure 14. Oncology Image Figure 15. Hormonal Disorder Image Figure 16. Metabolic Disorder Image Figure 17. Others Image Figure 18. Global Somatostatin Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Somatostatin Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Somatostatin Receptor Type 2 Sales Value Share by Application (2021-2032) Figure 21. Global Somatostatin Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Somatostatin Receptor Type 2 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Somatostatin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 24. North America Somatostatin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Somatostatin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Somatostatin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Somatostatin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Somatostatin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Somatostatin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 30. South America Somatostatin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Somatostatin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Somatostatin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • CRN-00808
  • PRL-2903
  • Lanreotide Acetate
  • Others
Applications
  • Oncology
  • Hormonal Disorder
  • Metabolic Disorder
  • Others
Companies covered
  • Amryt Pharma plc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Ipsen SA
  • Progenics Pharmaceuticals Inc
  • Strongbridge Biopharma plc
  • Zucara Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Somatostatin Receptor Type 2 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Somatostatin Receptor Type 2 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Somatostatin Receptor Type 2 Market Dynamics
  1. 2.1 Somatostatin Receptor Type 2 Industry Trends
  2. 2.2 Somatostatin Receptor Type 2 Industry Drivers
  3. 2.3 Somatostatin Receptor Type 2 Industry Opportunities and Challenges
  4. 2.4 Somatostatin Receptor Type 2 Industry Restraints
3 Somatostatin Receptor Type 2 Market by Company
  1. 3.1 Global Somatostatin Receptor Type 2 Company Revenue Ranking in 2025
  2. 3.2 Global Somatostatin Receptor Type 2 Revenue by Company (2021-2026)
  3. 3.3 Global Somatostatin Receptor Type 2 Company Ranking (2024-2026)
  4. 3.4 Global Somatostatin Receptor Type 2 Company Manufacturing Base and Headquarters
  5. 3.5 Global Somatostatin Receptor Type 2 Company Product Type and Application
  6. 3.6 Global Somatostatin Receptor Type 2 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Somatostatin Receptor Type 2 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Somatostatin Receptor Type 2 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Somatostatin Receptor Type 2 Market by Type
  1. 4.1 Somatostatin Receptor Type 2 Type Introduction
  2. 4.1.1 CRN-00808
  3. 4.1.2 PRL-2903
  4. 4.1.3 Lanreotide Acetate
  5. 4.1.4 Others
  6. 4.2 Global Somatostatin Receptor Type 2 Sales Value by Type
  7. 4.2.1 Global Somatostatin Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Somatostatin Receptor Type 2 Sales Value by Type (2021-2032)
  9. 4.2.3 Global Somatostatin Receptor Type 2 Sales Value Share by Type (2021-2032)
5 Somatostatin Receptor Type 2 Market by Application
  1. 5.1 Somatostatin Receptor Type 2 Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Hormonal Disorder
  4. 5.1.3 Metabolic Disorder
  5. 5.1.4 Others
  6. 5.2 Global Somatostatin Receptor Type 2 Sales Value by Application
  7. 5.2.1 Global Somatostatin Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Somatostatin Receptor Type 2 Sales Value by Application (2021-2032)
  9. 5.2.3 Global Somatostatin Receptor Type 2 Sales Value Share by Application (2021-2032)
6 Somatostatin Receptor Type 2 Regional Value Analysis
  1. 6.1 Global Somatostatin Receptor Type 2 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Somatostatin Receptor Type 2 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Somatostatin Receptor Type 2 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Somatostatin Receptor Type 2 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Somatostatin Receptor Type 2 Sales Value (2021-2032)
  7. 6.3.2 North America Somatostatin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Somatostatin Receptor Type 2 Sales Value (2021-2032)
  10. 6.4.2 Europe Somatostatin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Somatostatin Receptor Type 2 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Somatostatin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Somatostatin Receptor Type 2 Sales Value (2021-2032)
  16. 6.6.2 South America Somatostatin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Somatostatin Receptor Type 2 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Somatostatin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
7 Somatostatin Receptor Type 2 Country-level Value Analysis
  1. 7.1 Global Somatostatin Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Somatostatin Receptor Type 2 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Somatostatin Receptor Type 2 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Somatostatin Receptor Type 2 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Somatostatin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Somatostatin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Somatostatin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amryt Pharma plc
  2. 8.1.1 Amryt Pharma plc Company Information
  3. 8.1.2 Amryt Pharma plc Business Overview
  4. 8.1.3 Amryt Pharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amryt Pharma plc Somatostatin Receptor Type 2 Product Portfolio
  6. 8.1.5 Amryt Pharma plc Recent Developments
  7. 8.2 Crinetics Pharmaceuticals Inc
  8. 8.2.1 Crinetics Pharmaceuticals Inc Company Information
  9. 8.2.2 Crinetics Pharmaceuticals Inc Business Overview
  10. 8.2.3 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
  12. 8.2.5 Crinetics Pharmaceuticals Inc Recent Developments
  13. 8.3 Daewoong Pharmaceutical Co Ltd
  14. 8.3.1 Daewoong Pharmaceutical Co Ltd Company Information
  15. 8.3.2 Daewoong Pharmaceutical Co Ltd Business Overview
  16. 8.3.3 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Product Portfolio
  18. 8.3.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  19. 8.4 Ipsen SA
  20. 8.4.1 Ipsen SA Company Information
  21. 8.4.2 Ipsen SA Business Overview
  22. 8.4.3 Ipsen SA Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ipsen SA Somatostatin Receptor Type 2 Product Portfolio
  24. 8.4.5 Ipsen SA Recent Developments
  25. 8.5 Progenics Pharmaceuticals Inc
  26. 8.5.1 Progenics Pharmaceuticals Inc Company Information
  27. 8.5.2 Progenics Pharmaceuticals Inc Business Overview
  28. 8.5.3 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
  30. 8.5.5 Progenics Pharmaceuticals Inc Recent Developments
  31. 8.6 Strongbridge Biopharma plc
  32. 8.6.1 Strongbridge Biopharma plc Company Information
  33. 8.6.2 Strongbridge Biopharma plc Business Overview
  34. 8.6.3 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Product Portfolio
  36. 8.6.5 Strongbridge Biopharma plc Recent Developments
  37. 8.7 Zucara Therapeutics Inc
  38. 8.7.1 Zucara Therapeutics Inc Company Information
  39. 8.7.2 Zucara Therapeutics Inc Business Overview
  40. 8.7.3 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Product Portfolio
  42. 8.7.5 Zucara Therapeutics Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst